Restricted accessResearch articleFirst published online 2025-04
Lactobacillus rhamnosus GG Combined with Metformin Alleviates Alcohol-Induced Liver Inflammation in Mice by Maintaining the Intestinal Barrier and Regulating Treg/Th1 Cells
Disturbances of the intestinal barrier enabling bacterial translocation exacerbate alcoholic liver disease (ALD). Lactobacillus rhamnosus GG (LGG) has been shown to exert beneficial effects in gut dysbiosis and chronic liver disease. The current study assessed the combined effects of LGG and metformin, which play roles in anti-inflammatory and immunoregulatory processes, in alcohol-induced liver disease mice. A diet comprising 5% alcohol for 4 weeks was employed to develop an alcohol-induced liver injury model. Mice were orally administered LGG, metformin, or their combination on alternate days. Tight junction (TJ) proteins, gut microbiome composition, inflammatory cytokines, Jun N-terminal kinase (JNK), and p38 signals were assessed. When compared with treatment with LGG or metformin alone, combined LGG and metformin treatment substantially lowered the symptoms of inflammation, steatosis, and elevated liver enzymes caused by alcohol administration. Combination treatment significantly improved intestinal microecology, evidenced by the recovery of intestinal flora, TJ proteins, and intestinal villi. Combination treatment reduced hepatic inflammation by blocking p38 and JNK phosphorylation. The combination of LGG and metformin corrected immune-response dysregulation and improved ALD by enhancing the intestinal microbiome, restoring mucosal barrier integrity, modulating immune function, and decreasing liver injury. These results provide information for the development of intestinal microbiota-based preventive and therapeutic agents against ALD.
Get full access to this article
View all access options for this article.
References
1.
ImPK, MillwoodIY, KartsonakiC, et al.;China Kadoorie Biobank (CKB) collaborative group. Alcohol drinking and risks of liver cancer and non-neoplastic chronic liver diseases in China: A 10-year prospective study of 0.5 million adults. BMC Med, 2021; 19(1):216; doi: 10.1186/s12916-021-02079-1
2.
PimpinL, Cortez-PintoH, NegroF, et al.;EASL HEPAHEALTH Steering Committee. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol, 2018; 69(3):718–735; doi: 10.1016/j.jhep.2018.05.011
3.
BjorkhaugST, AanesH, NeupaneSP, et al.Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption. Gut Microbes, 2019; 10(6):663–675; doi: 10.1080/19490976.2019.1580097
4.
LangS, FairfiedB, GaoB, et al.Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. Gut Microbes, 2020; 12(1):1785251; doi: 10.1080/19490976.2020.1785251
5.
PattenDA, ShepherdEL, WestonCJ, et al.Novel targets in the immune microenvironment of the hepatic sinusoids for treating liver diseases. Semin Liver Dis, 2019; 39(2):111–123; doi: 10.1055/s-0039-1678727
6.
MendesBG, SchnablB. From intestinal dysbiosis to alcohol-associated liver disease. Clin Mol Hepatol, 2020; 26(4):595–605; doi: 10.3350/cmh.2020.0086
7.
LeclercqS, MatamorosS, CaniPD, et al.Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A, 2014; 111(42):E4485–E4493; doi: 10.1073/pnas.1415174111
8.
WangR, TangR, LiB, et al.Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol, 2021; 18(1):4–17; doi: 10.1038/s41423-020-00592-6
9.
LangS, SchnablB. Microbiota and fatty liver disease-the known, the unknown, and the future. Cell Host Microbe, 2020; 28(2):233–244; doi: 10.1016/j.chom.2020.07.007
10.
WestenbergerG, SellersJ, FernandoS, et al.Function of mitogen-activated protein kinases in hepatic inflammation. J Cell Signal, 2021; 2(3):172–180.
11.
CanovasB, NebredaAR. Diversity and versatility of p38 kinase signalling in health and disease. Nat Rev Mol Cell Biol, 2021; 22(5):346–366; doi: 10.1038/s41580-020-00322-w
12.
YangL, WuD, WangX, et al.Cytochrome P4502E1, oxidative stress, JNK, and autophagy in acute alcohol-induced fatty liver. Free Radic Biol Med, 2012; 53(5):1170–1180; doi: 10.1016/j.freeradbiomed.2012.06.029
13.
AlmeidaJ, PolvorosaMA, Gonzalez-QuintelaA, et al.Decreased peripheral blood CD4+/CD25+ regulatory T cells in patients with alcoholic hepatitis. Alcohol Clin Exp Res, 2013; 37(8):1361–1369; doi: 10.1111/acer.12095
14.
McTernanPM, LevittDE, WelshDA, et al.Alcohol impairs immunometabolism and promotes naive T cell differentiation to pro-inflammatory Th1 CD4(+) T Cells. Front Immunol, 2022; 13:839390; doi: 10.3389/fimmu.2022.839390
Gonzalez-ReimersE, Santolaria-FernandezF, Medina-GarciaJA, et al.TH-1 and TH-2 cytokines in stable chronic alcoholics. Alcohol Alcohol, 2012; 47(4):390–396; doi: 10.1093/alcalc/ags041
17.
NeumanMG, MuellerJ, MuellerS. Non-invasive biomarkers of liver inflammation and cell death in response to alcohol detoxification. Front Physiol, 2021; 12:678118; doi: 10.3389/fphys.2021.678118
18.
NivukoskiU, BloiguA, BloiguR, et al.Comparison of serum calprotectin, a marker of neutrophil activation, and other mediators of inflammation in response to alcohol consumption. Alcohol, 2021; 95:45–50; doi: 10.1016/j.alcohol.2021.06.001
19.
CapursoL. Thirty years of lactobacillus rhamnosus GG: A review. J Clin Gastroenterol, 2019; 53 (Suppl 1):S1–S41; doi: 10.1097/MCG.0000000000001170
20.
WangY, LiuY, KirpichI, et al.Lactobacillus rhamnosus GG reduces hepatic TNFalpha production and inflammation in chronic alcohol-induced liver injury. J Nutr Biochem, 2013; 24(9):1609–1615; doi: 10.1016/j.jnutbio.2013.02.001
21.
ChenRC, XuLM, DuSJ, et al.Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function, balances Treg and TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding. Toxicol Lett, 2016; 241:103–110; doi: 10.1016/j.toxlet.2015.11.019
22.
CaiC, ChenDZ, GeLC, et al.Synergistic effects of Lactobacillus rhamnosus culture supernatant and bone marrow mesenchymal stem cells on the development of alcoholic steatohepatitis in mice. Am J Transl Res, 2019; 11(9):5703–5715.
23.
Sanchez-RangelE, InzucchiSE. Metformin: Clinical use in type 2 diabetes. Diabetologia, 2017; 60(9):1586–1593; doi: 10.1007/s00125-017-4336-x
24.
XuL, WangX, ChenY, et al.Metformin modulates T cell function and alleviates liver injury through bioenergetic regulation in viral hepatitis. Front Immunol, 2021; 12:638575; doi: 10.3389/fimmu.2021.638575
25.
HajiaghamohammadiAA, ZiaeeA, OveisiS, et al.Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: A randomized controlled pilot study. Hepat Mon, 2012; 12(8):e6099; doi: 10.5812/hepatmon.6099
26.
Seif El-DinSH, SalemMB, El-LakkanyNM, et al.Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. Hum Exp Toxicol, 2021; 40(9):1496–1509; doi: 10.1177/0960327121999445
27.
ChiuHY, TsaiSC, TsaiFJ, et al.Liraglutide with metformin therapy ameliorates hepatic steatosis and liver injury in a mouse model of non-alcoholic steatohepatitis. In Vivo, 2023; 37(3):1037–1046; doi: 10.2187/3/invivo.13178
28.
ZhangX, ZhaoY, XuJ, et al.Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep, 2015; 5:14405; doi: 10.1038/srep14405
29.
PalaciosT, VitettaL, CoulsonS, et al.Targeting the intestinal microbiota to prevent Type 2 diabetes and enhance the effect of metformin on glycaemia: A randomised controlled pilot study. Nutrients, 2020; 12(7); doi: 10.3390/nu12072041
30.
BolyenE, RideoutJR, DillonMR, et al.Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol, 2019; 37(8):852–857; doi: 10.1038/s41587-019-0209-9
31.
CallahanBJ, McMurdiePJ, RosenMJ, et al.DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods, 2016; 13(7):581–583; doi: 10.1038/nmeth.3869
32.
LiS, TanHY, WangN, et al.Recent insights into the role of immune cells in alcoholic liver disease. Front Immunol, 2019; 10:1328; doi: 10.3389/fimmu.2019.01328
33.
CassardAM, CiocanD. Microbiota, a key player in alcoholic liver disease. Clin Mol Hepatol, 2018; 24(2):100–107; doi: 10.3350/cmh.2017.0067
34.
HuangW, KongD. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. Biomed Pharmacother, 2021; 135:111235; doi: 10.1016/j.biopha.2021.111235
35.
ZhuZ, JiangZ, ZhouJ, et al.Involvement of insulin resistance in the protective effect of metformin against alcoholic liver injury. Alcohol Clin Exp Res, 2014; 38(6):1510–1519; doi: 10.1111/acer.12418
36.
ItzelT, FalconerT, RoigA, et al.Efficacy of co-medications in patients with alcoholic liver disease. Dig Dis, 2023; 41(5):780–788; doi: 10.1159/000529914
37.
XieF, ZhongY, WangD, et al.Metformin protects against ethanol-induced liver triglyceride accumulation by the LKB1/AMPK/ACC pathway. Mol Biol Rep, 2022; 49(8):7837–7848; doi: 10.1007/s11033-022-07610-y
38.
AkinwunmiMT, AdisaRA, AroyeunSO, et al.Ethanolic extract of Camellia sinensise licited hypoglycemic but lacked antimalarial properties in Plasmodium berghei-infected diabetic mice. Niger J Physiol Sci, 2021; 36(2):189–194; doi: 10.5454/8/njps.v36i2.7
39.
ChungEJ, DoEJ, KimSY, et al.Combination of metformin and VSL#3 additively suppresses western-style diet induced colon cancer in mice. Eur J Pharmacol, 2017; 794:1–7; doi: 10.1016/j.ejphar.2016.11.012
40.
d’HennezelE, AbubuckerS, MurphyLO, et al.Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling. mSystems, 2017; 2(6); doi: 10.1128/mSystems.00046-17
41.
HiippalaK, JouhtenH, RonkainenA, et al.The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation. Nutrients, 2018; 10(8); doi: 10.3390/nu10080988
42.
LlopisM, CassardAM, WrzosekL, et al.Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut, 2016; 65(5):830–839; doi: 10.1136/gutjnl-2015-310585
43.
RaoR. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology, 2009; 50(2):638–644; doi: 10.1002/hep.23009
44.
MaJ, CaoH, RodriguesRM, et al.Chronic-plus-binge alcohol intake induces production of proinflammatory mtDNA-enriched extracellular vesicles and steatohepatitis via ASK1/p38MAPKalpha-dependent mechanisms. JCI Insight, 2020; 5(14); doi: 10.1172/jci.insight.136496
45.
LinF, TaylorNJ, SuH, et al.Alcohol dehydrogenase-specific T-cell responses are associated with alcohol consumption in patients with alcohol-related cirrhosis. Hepatology, 2013; 58(1):314–324; doi: 10.1002/hep.26334
46.
WangH, WuT, WangY, et al.Regulatory T cells suppress excessive lipid accumulation in alcoholic liver disease. J Lipid Res, 2019; 60(5):922–936; doi: 10.1194/jlr.M083568
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
